nChroma Bio

Biotech · Private

Epigenetic editing platform with targeted in vivo delivery technology

nchromabio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
23
1 granted · 22 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3128MYRIEL, INC.——
3129MABSWITCH, INC.——
3130KINEA BIO, INC.——
3131nChroma Bio——
3132ATB Therapeutics——
3133Flux Therapeutics, LLC——
3134Engrail Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 23
  • Guide Rna Compositionsapplication
  • Compositions And Methods For Epigenetic Regulation Of Hbv Gene Expressionapplication
  • Compositions And Methods For Epigenetic Regulation Of Hbv Gene Expressiongranted
  • Compositions And Methods For Epigenetic Regulation Of B2M Expressionapplication
  • Compositions And Methods For Epigenetic Regulation Of Trac Expressionapplication
  • Compositions And Methods For Epigenetic Editingapplication
  • Compositions And Methods For Epigenetic Editingapplication
  • Compositions And Methods For Epigenetic Regulation Of ZNF410 Expressionapplication
  • Compositions And Methods For Epigenetic Editingapplication
  • Compositions And Methods For Epigenetic Editingapplication
  • Lipid Delivery Particles And Uses Thereofapplication
  • Compositions And Methods For Epigenetic Editingapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.